SIP
FPRX

Stoneridge Investment Partners’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Stoneridge Investment Partners’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-21,905
Closed -$501K – 312
2015
Q1 		$501K Buy
+21,905
New +$553K 0.06% 206

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Stoneridge Investment Partners's FPRX Position: Q2 2015 in Review

Stoneridge Investment Partners sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2015, closing a stake of 21,905 shares — an estimated $501K sold.

Stoneridge Investment Partners first reported a position in FPRX in Q1 2015 and held it in 1 quarter. The position peaked at $501K in Q1 2015. 107 funds tracked by Wall St. Rank hold FPRX as of Q2 2015.

  • Stoneridge Investment Partners reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Stoneridge Investment Partners sold 21,905 Five Prime Therapeutics, Inc. shares in Q2 2015, an estimated $501K.
  • Stoneridge Investment Partners first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Stoneridge Investment Partners's Five Prime Therapeutics, Inc. position peaked at $501K in Q1 2015.
  • 107 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2015.

Based on Stoneridge Investment Partners's 13F filing for Q2 2015, filed 29 Jul 2015.